Exco InTouch Announces 1 Million Patients Supported Globally Through its Highly Scalable and Industry Leading Platform
![](/46/pdcnewsitem/03/43/84/xu2EG04NieIQuVi.png)
Exco InTouch has announced that one million patients have now benefited from the company’s firmly established and industry leading platform. This significant number underlines the company’s established leadership position in the market and highlights the broad reach of Exco InTouch’s services.
The company’s platform is highly scalable with the proven capability to support cross-border programmes with large patient populations. As a consequence, at any one time hundreds of thousands of patients across multiple territories, time zones and languages benefit from Exco InTouch’s software and services. The geographic spread has so far encompassed patients in a multitude of clinical and healthcare programs across 70 different languages in 26,000 hospitals and clinics across the globe.
Comprehensive regulatory understanding and compliance underlies Exco InTouch’s growth and consistent track record of international success and is an essential attribute for managing clinical and health programs globally. The company is compliant to HIPAA, HITECH, Safe Harbor and international data protection and privacy regulations; thereby marking Exco InTouch out as the most compliant of all the digital patient engagement and data capture solutions providers.
Dale Jessop, Chief Technology Officer at Exco InTouch commented: “The capability to scale-up and to meet head on the challenge of modern clinical and health programmes is the key to success in the complex markets that we serve. To achieve this our platform has been developed to enable delivery of tailored digital and mobile solutions to large numbers of patients, each with different technological needs and expectations, across an array of different regions, languages and cultures.”
He added: “In the fast changing world of digital and mobile technology, the trick is to have the foresight and efficiency to rapidly evolve software and technology with the speed necessary to ensure that effective solutions, that actively engage patients and capture their data, are deployed seamlessly. Furthermore, sufficient investment is of critical importance to provide full confidence that resources are in place to sufficiently guarantee that platforms really are robust enough to meet the demands of servicing such large numbers of patients simultaneously, and on the global scale required, across all the multiple territories concerned.”
Tim Davis, CEO of Exco InTouch commented: “We are of course very pleased that our leading global expertise, knowledge, software and capabilities have been put to use in the servicing of clinical and healthcare programmes on such a scale, enabling the benefits of our advanced offering to be experienced by over a million patients. Indeed, we look forward to many more patients benefiting from our engaging solutions as we continue to expand and develop our advanced capabilities in the industry.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance